PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed price. Currency in USD
6.22
+0.18 (+2.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close6.04
Open6.09
Bid6.03 x 500
Ask6.51 x 500
Day's range6.04 - 6.26
52-week range4.60 - 11.72
Volume809,254
Avg. volume1,069,298
Market cap437.078M
Beta3.61
PE ratio (TTM)N/A
EPS (TTM)-0.80
Earnings date7 Mar 2018 - 12 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.75
Trade prices are not sourced from all markets
  • Globe Newswire13 days ago

    Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions — Future Expectations, Projections Moving into 2018

    NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Gevo, Inc. (NASDAQ:GEVO), OSI Systems, Inc. (NASDAQ:OSIS), Senseonics Holdings, Inc. (NYSE:SENS), and Donnelley Financial Solutions Inc. (NYSE:DFIN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

  • Globe Newswire16 days ago

    Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404

    Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that it has completed enrollment in its Phase 3 study of 1404, a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. “The results of this large-scale Phase 3 study will provide important insights on the potential of our novel imaging agent to accurately and non-invasively detect and monitor patients with low-grade prostate cancer,” said Mark Baker, Chief Executive Officer of Progenics. The Phase 3 study enrolled approximately 450 patients in the U.S. and Canada with newly-diagnosed or low-grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and/or are candidates for active surveillance.

  • Associated Press20 days ago

    Goldman Sachs and Hess slide while PepsiCo and TiVo rise

    Stocks that moved substantially or traded heavily Friday: Adtran Inc., down $2.90 to $19.35 The networking equipment maker gave weak revenue forecasts because a major customer is spending less. Bonanza ...

  • Why Progenics Pharmaceuticals, Inc.'s Shareholders Came to Their Senses
    Motley Fool20 days ago

    Why Progenics Pharmaceuticals, Inc.'s Shareholders Came to Their Senses

    The biotech progresses, but it should have been expected.

  • MarketWatch20 days ago

    Progenics shares jump 21% premarket after FDA says it will review treatment for rare cancer

    Shares of Progenics Pharmaceuticals Inc. surged 21% in premarket trade Friday, after the company said the U.S. Food and Drug Administration has accepted for review its new drug application for Azedra in ...

  • Globe Newswire20 days ago

    Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma

    Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for AZEDRA® in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors.  The FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).

  • Associated Press3 months ago

    Progenics reports 3Q loss

    On a per-share basis, the New York-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $2.7 million in the period. Progenics shares have declined 32 percent since ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes